Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Expands By 645.3%

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 429,662 shares, a growth of 645.3% from the December 15th total of 57,651 shares. Based on an average daily volume of 690,991 shares, the short-interest ratio is presently 0.6 days. Approximately 81.5% of the shares of the stock are sold short. Approximately 81.5% of the shares of the stock are sold short. Based on an average daily volume of 690,991 shares, the short-interest ratio is presently 0.6 days.

SciSparc Price Performance

Shares of SPRC opened at $1.23 on Wednesday. SciSparc has a 1 year low of $1.00 and a 1 year high of $17.83. The company’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $3.78.

SciSparc (NASDAQ:SPRC) last issued its quarterly earnings results on Tuesday, November 18th. The company reported ($3.08) earnings per share for the quarter. The business had revenue of $0.23 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.